Acino is a pharmaceutical company based in Switzerland, established in 1836, that specializes in developing, manufacturing, and distributing high-quality medicines, particularly for emerging markets. Acino focuses on treating a range of health conditions including acid reflux, cardiovascular diseases, and infectious diseases. The company is committed to sustainability, aiming for full carbon neutrality by 2050, and it pursues partnerships for out-licensing and contract manufacturing to ensure broad accessibility of its medicines. Acino has expanded its operations through strategic acquisitions, such as M8 Pharmaceuticals in Latin America, and is focused on pharmaceutical growth and innovation across regions like Africa, Middle East, and Latin America. The company is dedicated to maintaining high-quality standards in all its activities and works towards environmental, social, and governance goals.